Amrubicin

From Self-sufficiency
Jump to: navigation, search
Amrubicin
File:Amrubicin.png
Systematic (IUPAC) name
(7S,9S)-9-Acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
Clinical data
Routes of
administration
IV
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
CAS Number 110267-81-7
ATC code none
PubChem CID 178149
ChemSpider 2299344
Chemical data
Formula C25H25NO9
Molar mass 483.46 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.[1] It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed.[2]

Amrubicin acts by inhibiting Topoisomerase II, and has been compared in clinical trials with Topotecan, a Topoisomerase I inhibitor.[3] [4]

It has also been studied for the treatment of bladder carcinoma[5] and gastric cancer.[6]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
ja:アムルビシン
  1. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. Sumitomo Pharmaceuticals Co., Ltd. (2003). "CALSED for Injection (English)" (PDF). Retrieved 2008-08-17. 
  3. Celgene Corporation (2008). "Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer". Retrieved 2009-07-10. 
  4. Medical News Today (2007). "Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer". Retrieved 2009-07-10. 
  5. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  6. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.